The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model

Clinical Cancer Research

Volumn 12, Issue 8, 2006, Pages 2602-2606

  Yang, Meng ^a   Burton, Doug W ^b   Geller, Jack ^a   Hillegonds, Darren J ^d   Hastings, Randolph H ^b   Deftos, Leonard J ^b   Hoffman, Robert M ^a,c  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; GREEN FLUORESCENT PROTEIN; OLPADRONIC ACID; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BONE RADIOGRAPHY; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CALCIUM; CELL LINE, TUMOR; DIPHOSPHONATES; DISEASE PROGRESSION; GLYCOPROTEINS; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MICE; MICE, NUDE; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646388648     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2050     Document Type: Article

References (25)

1. Karayi MK, Markham AF. Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis 2004;7:6-20.
2. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
3. Wu G, Iwamura M, di Sant'Agnese PA, Deftos LJ, Cockett AT, Gershagen S. Characterization of the cell-specific expression of parathyroid hormone-related protein in normal and neoplastic prostate tissue. Urology 1998;51:110-20.
4. Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 2005;327:468-72.
5. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001;57:611-6.
6. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005;173:10-20.
7. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004;8:1-176.
8. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
9. Zhang H, Yano S, Miki T, et al. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice. Clin Exp Metastasis 2003;20:153-9.
10. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996;14:2552-9.
11. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
12. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
13. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
14. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-8.
15. Burton DW, Geller J, Yang M, et al. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. Prostate 2005;62:275-81.
16. Yang M, Jiang P, Sun FX, et al. A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res 1999;59:781-6.
17. Hoffman RM. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol 2002;3:546-56.
18. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-9.
19. van der Pluijm G, Que I, Sijmons B, et al. Interference with the microenvironmental support impairs the De novo formation of bone metastasis in vivo. Cancer Res 2005;65:7682-90.
20. Xie A, Liao C, Li Z, et al. Quantitative-structure-activity relationship study of bisphosphonates. Internet Electron J Mol Des 2004;3:622-50.
21. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306.
22. Conte P, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin Oncol 2004;31:59-63.
23. Peyruchaud O, Serre CM, NicAmhlaoibh R, Fournier P, Clezardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem 2003;278:45826-32.
24. Pelger RC, Hamdy NA, Zwinderman AH, Lycklama a Nijeholt AA, Papapoulos SE. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998;22:403-8.
25. Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002;45:3721-38.